Our Product Discovery of Linaclotide Discovery of Linaclotide The diagram below illustrates the three dimensional structure of the linaclotide molecule. Linaclotide was discovered as a result of Ironwood’s pioneering research on the intestinal enzyme guanylate cyclase-C (GC-C) and went on to become the first GC-C agonist approved in the U.S., establishing GC-C agonists as a new class of medicines. GC-C is found mainly on the surface of the intestine and is thought to be a potential target for a variety of gastrointestinal diseases. Ironwood developed an orally available peptide – linaclotide – that selectively hits this target and can survive the harsh acidic environment of the stomach to reach GC-C in the intestine. Partnerships Collaboration is a core value and critical to our success Learn More Our Company Our Values Our Executive Team Our Board of Directors Open Payments and Transparency Our Product Discovery of Linaclotide Report a possible side effect Our Pipeline Partnerships Patients Join Us Open Positions Internships, Co-ops and Fellowships Things You Should Know Investors Events & Presentations Corporate Governance Financial Information Stock Information Investor FAQ Press Releases Investor Contacts Media Contact Us Follow Us Privacy Policy Terms of Use California Privacy Policy Site Map Contact Us Copyright © 2021, Ironwood Pharmaceuticals, Inc. All Rights Reserved LINZESS®, CONSTELLA®, IRONWOOD® and their associated logos are trademarks of Ironwood Pharmaceuticals, Inc. Any other trademarks referred to herein are the property of their respective owners. All rights reserved.